CARD14

Across TCGA pan-cancer cohorts, CARD14 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CARD14 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CARD14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CARD14 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where CARD14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.939	0.767	.001	14	view →
LUAD	DFS	Median	All	0.445	0.955	.011	7	view →
LSCC	DFS	Quartile	All	0.344	0.831	.038	2	view →
GBM	OS	Median	All	0.351	0.710	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CARD14–HNSC (OS)

Open the HNSC breakdown →